Patient or Disabled Group
Novartis Prepares to File Intrathecal Zolgensma for Older SMA Patients by Mid-2025
Zolgensma, intrathecal delivery, spinal muscular atrophy, gene therapy, older patients
Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes
Continuous Glucose Monitoring System, Technology, Health Personnel, CGM, Diabetes Mellitus, Non-Insulin-Dependent
Sarepta Reports Death of DMD Patient Following Elevidys Gene Therapy Treatment
Sarepta, Elevidys, gene therapy, Duchenne muscular dystrophy, patient death, acute liver failure
New Uplizna data drop in myasthenia gravis, while clock ticks on IgG4 decision
Uplizna, Myasthenia Gravis, Effectiveness, Improvement
Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer
Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market
Mineralys Phase 3 blood pressure pill data support potential FDA approval
United States Food and Drug Administration, Launch-HTN, Uncontrolled, Hypertensive disease, Approved
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
ARO-C3, IGA Glomerulonephritis, RNA Interference
AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits
Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis
Novo Nordisk Slashes Wegovy Price for Cash-Paying Patients
Wegovy, price cut, Novo Nordisk, NovoCare Pharmacy, obesity treatment, semaglutide, direct-to-patient, cash-paying patients